Attached files
| file | filename |
|---|---|
| EX-10.55 - Isoray, Inc. | v168105_ex10-55.htm |
United
States Securities And Exchange Commission
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of Earliest Event Reported): December 3, 2009
(December
2, 2009)
ISORAY, INC.
(Exact name of registrant as specified in its charter)
|
Minnesota
(State
or other jurisdiction
of
incorporation)
|
001-33407
(Commission
File
Number)
|
41-1458152
(IRS
Employer
Identification
No.)
|
350 Hills Street, Suite 106,
Richland, Washington 99354
(Address
of principal executive offices) (Zip Code)
(509)
375-1202
(Registrant's
telephone number)
ITEM 1.01
Entry into a Material Definitive Agreement
On
December 2, 2009, IsoRay Medical, Inc. ("Medical"), a wholly owned subsidiary of
IsoRay, Inc. (the "Registrant"), entered into a Distribution Agreement (the
"Agreement") with Oncura, Inc., a Delaware corporation ("Oncura"), with the
Agreement having an effective date of November 15, 2009. Under the Agreement,
Medical will be a non-exclusive distributor of Oncura’s Iodine-125 products in
the United States and Canada. The Agreement will expire on November 15, 2010
unless earlier terminated or renewed by the parties.
ITEM
9.01 Exhibits
|
|
(c)
|
Exhibits
|
|
10.55
|
Distribution
Agreement, dated effective November 15, 2009, by and between IsoRay
Medical, Inc. and Oncura, Inc. (confidential treatment requested for
redacted portions)
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated:
December 2, 2009
|
IsoRay,
Inc., a Minnesota corporation
|
|
|
By:
|
/s/ Dwight Babcock
|
|
Dwight
Babcock, CEO
|
|